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LFA-1 (CD 11 /CD 18)-DEFICIENT T CELLS TO CULTURED ENDOTHELIAL CELLS
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Patients with the leukocyte adhesion deficiency  
(LAD) syndrome have a genetic defect in  th e com ­
mon ¿2-chain (CD18) of the leukocyte integrins. This 
defect can result in th e absence o f ce ll surface  
expression of all three m em bers of th e  leu kocyte  
integrins. We investigated the capacity  o f T cell 
clones obtained from th e blood of an LAD patient 
and of normal T cell c lon es to adhere to  hum an  
umbilical vein endothelial cells (EC). A dhesion  o f  
the number of LAD T cells to  unstim ulated  EC w as 
approximately half of that of leu k ocyte function- 
associated antigen (LFA)-l* T cells. S tim ulation  o f  
EC with human rTNF-a resu lted  in an average 2- and  
2.5-fold increase in adhesion  of LFA-1* and LFA-1" 
cells, respectively. This effect w as m axim al after 24  
h and lasted for 48 to  72 h. The involvem ent o f  
surface structures known to  participate in  cell adhe­
sion (integrins, CD44) was tested  by b locking stu d ies  
with mAb directed against th ese  structures. A dhe­
sion of LFA-1+ T cells to  unstim ulated  EC w as inhib­
ited (average inhibition of 58%) with mAb to  C D lla  
or CD18. Considerably le ss  inhibition o f adhesion  
occurred with mAb to C D lla  or CD18 (average in ­
hibition, 20%) when LFA-1+ T cells  w ere incubated  
with rTNF-a-stimulated EC. The adhesion  of LFA-1" 
T cells to EC stim ulated w ith rTNF-a, but n ot to  
unstim ulated EC, was inhibited (average inhibition, 
56%) by incubation w ith a mAb directed to  very late  
antigen (VLA)-4 (CDw49d). In contrast to  LAD T cell 
clones and the LFA-1+ T cell line Jurkat, mAb to  
VLA-4 did not inhibit adhesion  of norm al LFA-1+ T 
cell clones to EC, whether or not th e  EC had been  
stim ulated with rTNF-a. We conclude th a t th e adhe­
sion m olecule pair LFA-1/intercellular adhesion  
m olecule (ICAM)-l p lays a major role in th e adhesion
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of LFA-14* T cell c lon es derived from norm al individ­
u a ls to  unstim ulated  EC. A dhesion of LFA-1 ~ T ce lls  
to  TNF-a-stim ulated EC is m ediated by VLA-4/vas- 
cular ce ll adhesion  m olecule (VCAM)-l interactions. 
Since w e were unable to  reduce significantly the  
adhesion  of cultured norm al LFA-1+ T cells to 24  h 
w ith TNF-a-stim ulated endothelium  with antibodies 
th at b lock LFA-l/ICAM-1 or VLA-4/VCAM-1 in ter­
actions, and lectin  adhesion  m olecule-1 and endo­
th elia l leu k ocyte  adhesion  m olecule-1 appeared not 
to  be im plicated, other as yet undefined cell surface  
structures are lik ely  to  participate in T cell/EC in ­
teractions.
Lymphocyte traffic allows continuous immune surveil­
lance of the body. In secondary lymphoid organs includ­
ing lymph nodes, tonsils, adenoids, Peyer’s patches, ap­
pendix, and mucosa-associated lymphoid tissues leuko­
cyte extravasation occurs predominantly in specialized 
postcapillary venules which are lined by high endothe­
lium (see Reference 1 for review).
Some of the adhesive properties of high endothelium 
in inflamed tissue can be mimicked by exposing cultured 
human umbilical vein EC5 to cytokines such as TNF-a (2, 
3), IL-1 (2, 3), or LPS (2). In man, leukocyte/EC interac­
tions may therefore be studied with cytokine-treated al­
logeneic cultured umbilical vein EC,
Several sets of adhesion molecules, e.g., the ligand/ 
receptor pairs leukocyte function-associated antigen 
(LFA)-l intercellular adhesion molecule (ICAM)-l (4), 
LFA-1 /ICAM-2 (5), very late antigen (VLA)-4/vascular cell 
adhesion molecule (VCAM)-l (6, 7), the lymphocyte hom­
ing receptor lectin adhesion molecule (LECAM)-l (8, 9), 
endothelial leukocyte adhesion molecule (ELAM)-l (10,
11), and the endothelial granule membrane protein-140 
molecule (12) are involved in the antigen-independent 
interaction of EC and leukocytes. The human counter­
structures of the last three molecules are as yet partly 
characterized (13). LFA-1 integrin expression on T cells 
from normal individuals strongly contributes to binding 
of these cells to their counterstructures on EC (11, 14,
5 Abbreviations used in this paper: EC, endothelial cell; PBS-BSA, PBS 
containing 0.01% CaCl2, 0.01% MgCl2 and 0,25% BSA; LFA, leukocyte 
function-associated antigen; ICAM, intercellular adhesion molecule; 
VCAM-1, vascular cell adhesion molecule-1; LECAM-1, lectin adhesion 
molecule-1; ELAM-1, endothelial leukocyte adhesion molecule-1; VLA, 
very late antigen; LAD, leukocyte adhesion deficiency; HEV, high endo­
thelial venule: ECGF, endothelial cell growth factor.
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15), thereby veiling the possible involvement of other 
molecules in the leukocyte/EC interaction. Therefore, in 
this study we investigated the adhesive properties of LFA- 
1~ T cells derived from a patient with leukocyte adhesion 
deficiency (LAD) to determine the contribution of other 
cell surface molecules in T cell/EC interactions. Com­
plexes of a' and 13' precursors of leukocyte integrins are 
required for processing and transport to the cell surface 
(16). We generated T cell clones from peripheral blood of 
a patient with LAD whose leukocytes completely lack cell 
surface expression of the three leukocyte integrin mole­
cules LFA-1, Mac-1, and p i 50,95 as a result of the in­
capability of the cells to produce mRNA coding for the /?2 
subunit of the leukocyte integrins.6 Such patients suffer 
from life-threatening recurrent bacterial infections and 
persistent neutrophilia. The impaired granulocyte-mon- 
ocyte function caused by this defect is demonstrated by 
the failure of migration and adhesion of the polymorpho­
nuclear leukocytes. LAD patients, however, have shown 
no clinical manifestation of defects in T cell or NK cell 
functions, suggesting that other adhesion pathways 
could be effectively utilized in lymphocytes in vivo to 
compensate for CD11/CD18 deficiency in these cells (17), 
In this study we have characterized cell surface mole­
cules that are involved in the adhesion of cytotoxic and 
noncytotoxic CD4+ and cytotoxic CD8+ T cell clones from 
both normal individuals and an LAD patient. The results 
demonstrate that the LFA-l/ICAM-1 interaction predom­
inantly mediates binding of T cells from healthy individ­
uals to unstimulated endothelium and that VLA-4/ 
VCAM-1 interaction plays a major role in the binding of 
T cells from LFA-1" patients to EC activated for 24 h by 
TNF-a.
Monoclonal an tibod ies . The mAb used in the adhesion test and 
their final concentrations are listed in Table I. No differences were 
observed between HPLC-purified antibodies and ascites. Additional 
mAb used for phenotyplng T cell clones and EC were obtained from 
several laboratories: CLB-10G11 (antl-VLA-2, CDw49b) (44) and C l7 
(anti-/33-integrin, CD41) (45] from A. Sonnenberg, Amsterdam; CLB- 
IL2R/1 (antl-IL-2R, CD25) (46) from R. van Lier, Amsterdam; CLB- 
FcR-granl (anti-Fc receptor III, CD16) (47) from P. Tetteroo, Amster­
dam; CLB-RAg-35 (anti-von Willebrand factor) (20) from J. van 
Mourik, Amsterdam; ENA-2 (anti-ELAM-1 )7 from J. Leeuwenberg, 
Maastricht; J143 (anti-VLA-3, CDW49c) (48) from E. Klein, Ulm; B- 
ly 6 (anti-pl50,95, C D llc) (49) from S. Poppema, Edmonton; TS2/ 
16 (anti-fr-lntegrin, CD29) (50) from T. Springer, Boston; and B- 
5G10 (anti-VLA-4, CDw49d) (51 j from M. Hemler, Boston. Leu8 (anti- 
LECAM-1) was obtained from Becton and Dickinson, San Jose, CA. 
32.2  (anti-Fc receptor I, CD64) (52) and IV.3 (anti-Fc receptor II, 
CD32) were purchased from Medarex Inc., West Lebanon, NH. NKI- 
Bearl (anti-CR3, C D llb] (27) and HP1/3 (anti-VLA-4, CDw49d) (37) 
have been described previously.
A d h e s io n  t e s t  Endothelial cells were trypsin treated, and 2 X 104 
cells In 100 /¿I of M l99 containing 20% heat-inactivated human 
serum (but without ECGF, heparin, and the components of chemi­
cally defined medium; see above) were seeded into 0.2% gelatin- 
coated 96-well plates (3596, Costar). After incubation overnight the 
cells were stimulated with human rTNF-« (supernatant of cDNA- 
transfected COS cells), using the concentrations indicated in the 
experiments. Before initiation of the adhesion experiment the wells 
were washed twice with 0.3 ml of sterile PBS-BSA, and the wells 
were filled with 100 of DMEM containing 25 mM HEPES, pH 7.0, 
and 0.25% BSA. Subsequently, 50 1^ containing 5,000 to 10,000 T 
cells that had been labeled with [51Cr]Na2Cr04 (350 to 600 mCi/mg; 
Amersham International, Buckinghamshire, UK; 0.1 mCi/5 X 106 
cells, followed by washing three times in DMEM) were added. Adhe­
sion w as allowed for 30 min at 37°C in the C 02 incubator. Non­
adherent cells were removed by washing three times with 0.3 ml of 
PBS-BSA. The adherent cells were solubilized for 30 min with 50 /¿I 
of 0.25% SDS, 1% Triton X-100, 0.5% sodium deoxycholate, and 5 
mM EDTA and counted in a gamma counter (Multi-Prias 1, Packard 
Instrument Co., Downers Grove, IL). Inhibition was calculated ac-
cording to the formula 
% inhibition = ( 1 -
cpm with mAb to test 
cpm with irrelevant control mAb,
x 100.
MATERIALS AND METHODS
EC. Human EC were isolated from umbilical vein by collagenase 
digestion (18). The cells were cultured in 0.2% gelatin-coated 75-cm 2 
flasks (3275, Costar, Cambridge, MA) in M l99 (Flow Laboratories, 
Irvine, Scotland) in the presence of penicillin and streptomycin  
(GIBCO Europe, Paisley, Scotland), 10% heat-inactivated hum an  
serum (Central Laboratory of the Blood Transfusion Service, Am­
sterdam, The Netherlands), bovine hypothalamus ECGF (5 Mg/ml, 
Boehringer Mannheim, FRG), heparin (10 ^g/ml, Sigma, St. Louis, 
MO), BSA (0.25%, fraction V, Boehringer Mannheim), and the ingre­
dients transferrin (0.036%), bovine pancreas insulin (5 M g / m l ) ,  lin- 
oleic acid (1 /tg/ml), oleic acid (1 /ug/ml), and palmitic acid (1 Mg/ml, 
all from Sigma), which have been described as components of a 
chemically defined medium for generating T cell clones (19). The 
cells were serially passaged by trypsin treatment. Cells from pas­
sages 4 through 7 were used for th e experiments. More than 95% of 
the cells were considered EC as they stained with mAb CLB-RAg-35 
to the von Willebrand factor (20) in an immunofluorescence test on 
acetone-fixed cells grown on fibronectin-coated coverslips.
T cells. The allo-MHC specific cytotoxic T cell clones J S 132 (CD8+) 
and JS136 (CD4H') were from the sam e individual and have been  
described previously by Borst et al. (21). The tetanus toxoid specific  
T-helper clone HY827 has been described by Yssel et al. (22). The 
LFA-1-negative T cell clones LAD1, LAD4, LAD6.6, and LAD19 were 
raised by limiting dilution of PBL from a patient with LAD lacking  
mRNA expression for the CD18 protein.6 The clones were grown in 
Iscove’s medium (Flow Laboratories) containing 5% heat-inactivated  
human serum by weekly stim ulation with 2 x 105 irradiated alloge­
neic PBL/ml and 1 x  10s EBV-transformed B cell line JY cells/m l in 
the presence of PH A (0.2 Mg/ml) and IL-2 (100 Cetus U/ml; 3 .2  X 106 
Cetus U/mg; Cetus Corp., Emeryville, CA). To avoid interference in 
the adhesion assays, the T cells were maintained in the presence of 
IL-2 but in the absence of feeder cells and PH A for 1 wk before 
testing. The EBV-transformed B cell line JY and the T cell line 
Jurkat were cultured in Iscove's medium containing 10% FCS.
6 Van de Wiel-Van Kemenade, E., A. A. Te Velde, A. J. De Boer, R. S. 
Weening, C. J. M. Melief, and C. G. Figdor. Cytotoxic activity of LFA-1
negative T cells is mediated through CD2/LFA-3. Subm itted  fo r  publi­
cation.
For inhibition experiments EC and lymphocytes were preincu­
bated with mAb and used without further washing.
F luorescence analysts . A  suspension of EC was obtained by 
digestion of EC cultures with collagenase (125 U/ml in 137 mM NaCl,
4  mM KC1, and 10 mM HEPES, pH 7.0) for 5 min at 37°C. EC and T 
cells were washed in ice-cold PBS containing 0.25% BSA and 0.02% 
NaN3 and suspended to 2 X 106 (EC) or 10 x 106 (T lymphocytes) 
cells/m l, Fifty /¿I were transferred to 5-ml tubes and incubated for 
30 m in at 4°C with 50 /¿I 1/500 diluted mAb containing ascites. The 
cells were washed with 2 ml of PBS containing 0.25% BSA and
0.02% NaN3 and incubated with 50 ¿d of affinity-purified goat anti­
m ouse IgG F(ab')2-FITC conjugate (100 Mg/ml antibody; Zymed, San 
Francisco, CA). The cells were washed once in PBS containing 0.02% 
NaNa in the presence of 0.25% BSA and once in PBS containing
0.02% NaN3 in the absence of BSA, fixed in 1.5% paraformaldehyde 
in PBS, and measured in the FACScan (Becton and Dickinson, 
Mountain View, CA). Antigen expression was presented as the mean 
fluorescence Intensity (arbitrary units).
RESULTS
Cell Surface Expression of T Cell Clones and EC
T cells. Analysis of cell surface molecules expressed by 
the cloned T cells JS132, JS136, LAD1, LAD4, LAD6.6, 
and LAD 19 is presented in Table II. No differences were 
observed between two cytotoxic LAD clones (LAD1 and 
LAD6.6) (P. Van de Wiel-van Kemenade, unpublished 
observations) and two non-cytotoxic LAD clones (LAD4 
and LAD 19). Furthermore, LFA-1+ and LFA-1 ~ T cell 
clones did not differ significantly in the expression of cell 
surface molecules other than leukocyte integrins. Nota­
bly, all of the T cell clones tested expressed an equal 
amount of VLA-4, irrespective whether they did or did
7 J. Leeuwenberg, Maastricht. The mAb is directed to a different epitope 
as ENA-1 (43).
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Mab u se d jo r  Inhibition of adhesion  oJT  cell clones to EC
Ag mAb
Ig Sub­
class Reference
Concentration 
of purified IgG 
(fig/ml)
DJlution 
of as­
cites
gplOO N K I/beteb lgG2b 23 25 1 / 1 0 0
HLA class 1 W 6 /3 2 IgG2a 24 48 1 / 1 0 0
HLA-DR/DP 9 5 /1 3 IgG2a 25 18
HLA-DQ SPV-L3 IgGl 26 41
CD3 SPV -T3b IgG 2a 26 , 27 1 / 1 0 0
CD4 CLB-T4/1 IgGl 28 1 / 1 0 0
CDS W T82 IgG2a 29 1 / 1 0 0
CD28 15E 8 IgG l 30 1 / 1 0 0
C D lla , LFA-1 NKI-L7 IgGl 31 2 2 1 / 1 0 0
CD 11c, p i 50 /95 S-HC1 3 IgG2 3 2 1 / 1 0 0
CD 18, /?2integrin CLB-LFA-1/1 IgG l 33 45
CD54, ICAM-1 F IO .2 IgG l a 1 / 1 0 0
CD58, LFA-3 T S 2 /9 IgGl 3 4 1 / 1 0 0
CD2 6G 4 IgG l 35 1 / 1 0 0
CD44, H erm es-1 NKI-Pl IgG l 36 1 / 1 0 0
CDw49d, VLA-4 H P2/1 IgG l 37 1 / 1 0 0
VLA-5 SAM-1 IgG2b 3 8 1 / 1 0 0
CDw49f, VLA-6 G0H3 IgG 2ab 39 1 / 1 0 0
CD51, VNR NKI-M9 IgG l 40 25
VC AM-1 2G 7 IgG l 41 1 /250
LECAM-1 DREG-5 6 IgG l 42 25
ELAM-1 ENA-2 IgG l C 1 0
aP. Bloemen, G. Moldenhauer, M. Van Dijk, H.-J. Schuurman, F, H. J. Gmelig Meyling, and A. C. Bloem. Multiple 
ICAM-1 (CD54) epitopes are Involved in homotyplc B cell adhesion. Scand* J. Immunol. 1992* in press. 
bRat mAb; others are murine mAb. 
cSee Footnote 7.
TABLE II
Phenotypic ana lysis  o f LFA-1" and  LFA-1 + T cell clones as ana lyzed  in the FACScan
Ag mAb LAD1 LAD4 LAD6.6 LAD19 JS132 JS136
HLA class I W6/32 ++a +4* 4-4* 4*4- 4-4-
HLA-DR/DP Q5/13 4-4* 4-4- 4*4* 4-4- ++ 4*4*
HLA-DQ SPV-L3 4- 4~H ++ 4- ++ 4-4-
CD3 SPV-T3b 4-4- 4*4- ++ *f+ ++ 4-4-
CD 4 CLB-T4/1 - 4-4- 4-4- ++ — 4-+
CD8 WT82 4*+ — _ — —
CD28 15E8 - - - — — —
CDlla, LFA-1 NKI-L7 - - — — 4-4-
CDllb, Mo-1 NKI-Bearl - - 4MI| — + 4-4-
CDllc, pl50/95 B-ly6 - — (+) (+)
CD 18, fointegrin CLB-LFA-1/1 - — — ++ 4*4-
CD54, ICAM-1 FIO.2 + + + 4-
CD58, LFA-3 TS2/9 + 4- + + + +
CD2 CLB-Tll.1/1 +4* 4-4- 4-4* ++ 4*4-
CD44, Hermes-1 NKI-P1 ++ w| ■ ++ 4-4* ++ 4-4-
CD29, /3jintegrin TS2/16 4-4- ++ 4*4* 4-4*
CDw49b, VLA-2 CLB-10G11 (+) Í+) 1+) (+) (+) (+)
CDw49c, VLA-3 J143 (+) — (+) — 4M* —
CDw49d, VLA-4 HP1/3, H P2/lb 4-4- + + +  + 4-4- + +
CDw49e, VLA-5 SAM-1 4- + + + 4- +
CDw49f, VLA-6 G0H3 — __ — — — —
CD41, fcintegrin C17 — - — — —
CD51, VNR NKI-M7 — - — — — —
LECAM-1 Leu8 NT* - NT — NT —
CD25, IL-2R CLB-IL2R/1 4- + + + 4- 4~ +
CD64, FCR I 32 .2 — ----------- — — — —
CD32, FcR II IV. 3 — — w p w i — — —
CD16, FcR III C L B -F cR -gran l — —
»
— — —
“Mean fluorescence intensity: < 10; (+), <  20; +, < 50; +4-, ^ 50. 
b Similar results were obtained with each mAb.
CNT, not tested.
not express the j32-chain of the leukocyte integrins 
(CD18). A striking feature was that in contrast to granu­
locytes and T lymphocytes that had been isolated from 
peripheral blood by centrifugal élutriation (not shown), 
the T cell clones lacked expression of LECAM-1, not only 
1 wk after restimulation of the cells with allogeneic lym­
phocytes (feeder cells) and PH A but also after culturing 
the cells for another wk in the presence of IL-2 only.
EC. The expression of cell surface molecules on EC is 
shown in Figure 1. After stimulation of EC with rTNF-a 
VCAM-1 was expressed de novo whereas the expression 
of ICAM-1 (CD54) had increased markedly, and the 
expression of the Hermes-1 Ag (CD44) and HLA-I class I
molecules had increased slightly. No expression was 
noticed of the HLA class II molecules HLA-DR/DP or 
HLA-DQ. Expression of the rapidly inducible adhesion 
molecule ELAM-1, which was highly expressed after 4 h 
of stimulation with rTNF-a (not shown), had faded away 
after 24 h in the presence of the cytokine.
Comparison of adhesion of T cell clones to EC
Adhesion of LFA-1*/LFA-r T cells. We first investi­
gated the ability of different T cell clones to adhere to 
both unstimulated and rTNF-a-stimulated EC. Maximal 
adhesion of both LFA-1* and LFA-1“ T cells was obtained 
after stimulation of EC with rTNF-o: for 24 h (Fig. 2).
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Relative fluorescence
Figure I. Phenotypic expression of surface molecules on EC as ana­
lyzed in the FACScan. EC were stimulated with 100 U/ml rTNF-a for 24  
h (-----; unstimulated EC ,-------).
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Figure 2. Adhesion of T cell clones to EC. EC were cultured in the 
presence of rTNF-a [•, 100 U/ml; A, 200 U/ml) or medium (O, control). 
JS136 and HY827 are antigen-specific CD4+ LFA-1+ T cell clones; LAD4 
and LAD 19 are CD4+ LFA-1” T cell clones. The SE bars represent three 
independent tests within a representative of two experiments. To enable 
proper comparison, the tests with JS136 and LAD4 were performed 
simultaneously, as were the tests with HY827 and LAD19.
Although the LFA-1"" T cell clones bound to untreated EC 
in much fewer num bers th a n  the  LFA-1* cells, the LFA- 
1” and LFA-1* T cells showed a similar enhancem ent of 
adhesion when the EC were pretreated with rTNF-a (Figs. 
2 and 3). From these resu lts  we conclude that although 
LFA-1- T cells showed reduced adhesion to EC because 
of absence of LFA-1/ICAM-1 and LFA-l/ICAM-2 in ter­
actions, T cells from LAD patien ts possess additional
a>
c
o
o
a>
o
JS132
JS136
HYB27
LAD 1 
LAD4 
LAD6.6
LAD19
n=1 
n=13 
h n= 1 1
I
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n=l 0
—i------ 1------ 1------ r—
20 40 60 80 60 80 100
% T cel l  a d h e r e n c e
] unstlmulated EC /////// TNF—a —stimulated EC
Figure 3. Adhesion of T cell clones to EC. EC were cultured in either 
the absence or the presence of rTNF-a (24 h, 100 U/ml). JS132 (LFA-1+) 
and LAD1 (LFA-1") are CD8+ cytotoxic T cell clones. LAD6.6 is a CD4+ 
LFA-1" cytotoxic T cell clone. See Figure 2 for a description of the other 
clones. The SE bars represent the number of different experiments 
performed (indicated by ri). Three independent tests were performed 
within each experiment.
molecules that are involved in adhesion to cytokine-stim­
ulated EC.
Cy to toxic/noncytotoxic T cells. No marked differences 
in adhesion to EC were obtained between the LFA-1+/ 
CD4+ cytotoxic T cell clone J S 136 and the tetanus toxoid- 
specific T helper cell clone HY827 (Fig. 2) or between the 
LFA-1 _/CD4+ cytotoxic T cell clone LAD6.6 compared 
with the noncytotoxic T cell clones LAD4 and LAD 19 
(Fig. 3).
CD4/CD8 T cells. Adhesion to EC of the LFA-1+/CD4+ 
T cell clones JS136 and HY827 was similar to that of the 
LFA-1+/CD8+ t  cell clone JS132. Likewise, adhesion of 
the LFA-1“/CD4+ T cell clones LAD4, LAD6.6, and 
LAD 19 was similar to tha t of the LFA-1"/CD8+ T cell 
clone LADl (Fig. 3).
Structures involved in adhesion of T cell clones to EC
To investigate which molecules are responsible for T 
cell adhesion, we incubated T cells as well as EC with 
mAb before the adhesion assay. Effects on adhesion to 
EC of the LFA-1+/CD8+ cytotoxic T cell clone JS132 and 
the LFA-1~/CD8+ cytotoxic T cell clone LADl, which, 
because of considerably slower growth rates than the 
CD4+ clones, were not available in sufficient amounts, 
were tested with a limited set of mAb (HLA class I, 
HLA-DR/DQ, CD3, CD8, LFA-1, p l50,95, the fo-chain of 
the leukocyte integrins, the Hermes-1 Ag (CD44), and the 
vitronectin receptor). The inhibition of JS132 by mAb 
was comparable to that obtained with JS136 and HY827. 
Likewise* the inhibition of adhesion of LADl by mAb was 
comparable with that of LAD4, LAD6.6, and LAD 19 (not 
shown). mAb to VCAM-1 was tested with JS136, HY827, 
and LAD 19 (see below). No difference was noticed 
w hether preincubation of T cells with mAb was per­
formed at 4 or 37°C or whether preincubation of T cells 
and EC was performed for 30 min vs 60 min (compare 
Fig. 4 with Figs. 6 and 7, and Fig. 5 with Fig. 6).
LFA-1/ICAM-1. Several groups have reported that the 
leukocyte integrins play an important role in adhesion to 
EC. Notably, LFA-1 (CDlla) is involved in adhesion of 
unstimulated and phorbol dibutyrate-stimulated periph­
eral T lymphocytes to unstimulated EC (14, 15, 53, 54). 
In our experiments adhesion of LFA-1+ T cell clones to
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Figure 4. Inhibition of adhesion of LFA-1+ (JS136) and LFA-1“ 
[LAD 19) T cells to EC by different mAb. Stimulation of EC was with 100 
U/ml rTNF-a for 24 h. Preincubation with mAb was for 60 min at 37°C, 
The SE bars represent three Independent tests of an average of five 
experiments. The asterisks  represent significant reduction of adhesion 
in a one-sided t-test compared with the incubation lacking mAb, in which 
*, p = 0.01 and ° , p =  0.005. mAb to gplOO, a melanosomal protein 
specific for cells of the melanocyte lineage (27), was used as a control 
antibody.
unstimulated EC was inhibited 58% (mean of 24 experi­
ments) by mAb to the LFA-1 a-chain (CDlla) or the 
common /?2-chain of the leukocyte integrins (CD 18) (see 
also JS136 and HY827 in Figs. 6 through 7). Inhibition 
of adhesion of LFA-1 * T cell clones by mAb to either LFA- 
1 (CD 11 a) or CD 18 was either much lower or absent when 
the EC had been stimulated with rTNF-a (Figs. 4 through 
7), Results obtained after simultaneous treatment of 
LFA-1* T cell clones with mAb to CD1 la  and CD 18 were 
similar to those obtained with treatment with either mAb 
alone (Fig. 5). With mAb to ICAM-1 (CD54), which is one 
of the counterstructures of LFA-1 on endothelial cells, 
inhibition of adhesion of LFA-1 * T cells to unstimulated 
EC was far less (23% inhibition of adhesion; Fig. 4].
Effect of phorbol ester. PMA has been shown to en­
hance LFA-1-dependent adhesion of T lymphocytes to 
cultured EC (14, 15, 53, 54). Anti-LFA-1 antibodies in­
hibited (69% inhibition) the 2.5-fold enhanced adhesion 
of HY827 cells that had been pretreated with the phorbol 
ester PMA to unstimulated EC (data not shown). Pretreat­
ment of LFA-1* T cells with PMA had no effect on the 
adhesion to rTNF-a-stimulated EC. Together, our results 
with cloned T cells show that LFA-1 is the main structure
Monoclonal antibody
HY827
gplOO, control
CD11 a 
CD15 
C D lla  +  CD1B
CD44 
CD44 +  CD18
CD58
CD2
CD58 +  CD2 
CD2 +  CD18 
CD58 + CD2 + CD11a
)
D
>
}
) **
vmrnmmw
0 20 40 60 80 0 20 40 SO 80 100
% T cell adherence
_________1 I unstimulatad EC KEÏÏ T N F -a -s tlm u la fad  EC
Figure 5. Adhesion of HY827 T cells to EC after simultaneous incu­
bation with different mAb. Preincubation with mAb was for 60 min at 
37°C. Stimulation of EC was for 24 h with 100 U/ml rTNF-a. Preincuba­
tion with mAb was for 60 min at 37°C. The SE bars represent three 
independent tests within the experiment. One representative out of three 
experiments is shown. See the legend of Figure 4 for an explanation of 
the asterisks.
involved in adhesion of T cells to unstimulated but not to 
rTNF-«-stimulated EC (24 h) and confirm the finding of 
others (14, 15, 53, 54) that PMA primarily stimulates 
LFA-1-dependent adhesion.
Role of VLA-4/VCAM-1. A structure on mouse lympho­
cytes showing homology with the human VLA-4 molecule 
is involved in adhesion to Peyer’s patches and mucosal 
HEV (55). Several investigators have reported that in man 
adhesion of T lymphocytes and some T and B lymphoid 
cell lines to TNF-a- or IL-1-stimulated EC can be inhibited 
by antibodies both against VLA-4 and its counterstruc­
ture on the EC VCAM-1 (6, 41, 54, 56-58). However, in 
our experiments the binding of LFA-1*/CD4* cytotoxic 
and T helper cell clones JS136 and HY827 to EC was not 
affected either by anti-VLA-4 or by anti-VCAM-1 anti­
body, whether or not these EC had been stimulated with 
rTNF-a (Figs. 4, 6, and 7). Neither did incubation with 
anti-LFA-1 in the presence of anti-VLA-4 antibodies re­
duce the adhesion of these LFA-1* T cells to TNF-a- 
stimulated EC (Fig. 6). This was not because of the anti- 
VLA-4 antibody used inasmuch as it was effective in 
inhibiting (70%) adhesion of the LFA-l-positive/ICAM-1- 
negative T cell line Jurkat to EC that were stimulated by 
rTNF-a. Adhesion to rTNF-a-stimulated, but not unstim­
ulated, EC of the cytotoxic (LAD6.6) and the two noncy­
totoxic (LAD4 and LAD 19) CD4+ LFA-1“ T cell clones 
tested was inhibited (average inhibition of 56%; mean of 
13 experiments) by anti-VLA-4 (Figs. 6 and 7). An inhi­
bition of 33% was obtained with mAb to VCAM-1 (Fig. 4). 
These results indicate that LFA-1” T cells, like the LFA- 
1* cell line Jurkat, adhere to rTNF-a-stimulated, but not 
to unstimulated, EC via the receptor/ligand pair VLA-4/ 
VCAM-1. Since the adhesion of Jurkat cells to EC resem­
bled more that of LFA-1" than that of LFA-1* T cells, the 
LFA-1 molecules on Jurkat cells are possibly not, or not 
fully, functional.
CD44. The Hermes-1 Ag is mainly involved in binding 
of PBL to mucosal and synovial lymph node and to a 
lesser extent to peripheral lymph node HEV (59). Previ­
ously, a different mAb (NKI-P1) to this Ag was prepared 
which also inhibited adhesion of PBL to peripheral lymph
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Figure 6. Inhibition of adhesion of Jurkat, JS136, HY827, LAD4, and LAD6.6 to EC by mAb directed against VLA-4 (CDw49d), LFA-1 (CDlla), 
the /?2-chain of the leukocyte Integrins (CD 18), or a mixture of these mAb. Stimulation of EC was for 24 h with 100 U/ml rTNF-a. Preincubation of T 
cells with mAb was for 30 min at 4°C. The SE bars represent three independent tests within the experiment, A representative of two experiments Is 
shown. See the legend of Figure 4 for an explanation of the asterisks.
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Figure 7. Inhibition of adhesion of JS136, LAD6.6, and LAD4 to EC by mAb directed against VLA-4 (CDw49d), LFA-1 (CD1 la), the /32-chaIn of the 
leukocyte integrins [CD 18), ELAM-1, or a mixture of these mAb. Stimulation of EC was for 24 h with 100 U/ml rTNF-a, Preincubation of T cells with 
mAb was for 30 min at 4°Ct and preincubation of EC with mAb to ELAM-1 was for 30 min at 37°C. The SE bars represent three independent tests 
within the experiment. A representative of two experiments is shown. See the legend of Figure 4 for an explanation of the asterisks.
node HEV but at the same time stimulated homotypic 
aggregation of cells of the EBV-transformed cell line JY 
(36). In tests with cloned T cells, however, we never 
observed inhibition of adhesion to (TNF-a-stimulated) EC. 
Instead, in 6 out of 14 experiments we observed more 
than 50% increased adhesion of cloned T cells by this 
mAb to unstimulated EC (Figs. 4 and 5). The increased 
adhesion was observed with both cytotoxic and noncy­
totoxic LFA-1* and LFA-1" CD4* T cell clones and was
not dependent on preincubation of the T cells with anti- 
CD44 at 37°C compared with 4°C. The enhanced adhe­
sion to unstimulated EC was only partially reduced by 
mAb to CD 18 (Fig. 5). There are several explanations for 
this phenomenon, which will be discussed below.
No marked inhibitory or stimulatory effects on adhe­
sion of the LFA-1* or LFA-1~ T cell clones to rTNF-c*- 
stimulated or unstimulated EC were observed with any 
of the other mAb tested, neither with mAb to CD8 and
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CD4, nor with mAb to LFA-3 and CD2 (Figs. 4 and 5). 
LFA-3 and CD2 have been shown recently to be involved 
in EC- augmented IL-2 production in T cells (60). In 
analogy with the observation with neutrophils (8, 42, 61), 
the cultured T cell clones probably lose LECAM-1 expres­
sion because they are activated during in vitro culturing. 
In accordance with this finding, no inhibition of adhesion 
of LFA-1* or LFA-1” T cells to EC was observed with the 
inhibiting mAb DREG-56 (42) (Fig. 4). ELAM-1, which is 
implicated in preferential adhesion of memory T lympho­
cytes to EC in the skin (11, 62), was, as discussed before, 
also not present any more on the EC after incubation 
with rTNF-a for 24 h (Fig. 1), and we found no inhibition 
of adhesion of cloned T cells after incubation of stimu­
lated EC with anti-ELAM-1 mAb (Fig. 7).
DISCUSSION
The main points emerging from this study with T cell 
clones are the following. 1) LFA-1~ T cells show reduced 
adhesion to EC compared with LFA-1* cells. 2) Stimula­
tion of EC with TNF-a enhances adhesion of LFA-1* and 
LFA-1" T cells. 3) Adhesion of LFA-1* T cells to unstim­
ulated EC is LFA-1 dependent. 4) Adhesion of PMA- 
activated T cells to unstimulated EC is increased and is 
LFA-1 dependent. 5) VLA-4 mediates adhesion of LFA- 
1“ T cells to TNF-a-stimulated EC but not unstimulated 
EC. 6) Because VLA-4 does not mediate adhesion of 
cloned LFA-1* T cells to TNF-a-stimulated (24 h) EC and 
because LECAM-1 or ELAM-1 did not contribute to adhe­
sion of these cells, a new, as yet undefined, adhesion 
structure(s) must exist.
LECAM-1, which is implicated in adhesion of (memory) 
T cells and neutrophils to peripheral lymph node HEV (8, 
9, 42), was not expressed by the T cell clones studied. 
Preliminary experiments (not shown) show that upon 
activation with PMA, peripheral T cells lose LECAM-1 
expression similarly to what has been described for neu­
trophils (61). Therefore, LECAM-1 expression is not im­
plicated in T cell adhesion to EC in our study.
LFA-1/ICAM-1 and VLA-4/VCAM-1 interactions have 
been reported to play a role in adhesion of peripheral 
blood T lymphocytes to cultured EC (4, 14, 41, 53, 58). In 
addition, ELAM-1 has been shown recently to mediate 
adhesion of CD4* memory cells to 4- to 6-h rIL-1-stimu­
lated EC (41, 54), We have deliberately stimulated the EC 
for 24 h with rTNF-a because after this period of time 
maximal adhesion of cloned T cells was obtained (Fig. 2). 
Preliminary experiments indicate also that after 24 h of 
stimulation of EC with rIL-1/3 maximal adhesion of these 
T cells is obtained (data not shown). However, after this 
prolonged incubation ELAM-1 is hardly expressed on EC 
(10, 43), thus excluding a role of ELAM-1 in this study.
VCAM-1 and ICAM-1, the Hermes-1 Ag (CD44), were 
up-regulated after stimulation of EC with rTNF-a. Our 
results with T cell clones show that VLA-4/VCAM-1 is 
an important alternative pathway if LFA-1/ICAM-1 in­
teractions are absent. The data with LFA-1* T cell clones 
are in contrast with data obtained with resting or PMA- 
stimulated peripheral T lymphocytes, their adhesion to 
activated EC being inhibited by a mixture of mAb to LFA- 
1 and either VLA-4 or VCAM-1 (7, 41, 54). Therefore, we 
conclude that cloned T cells, which are cultured in the 
presence of IL-2 and are strongly activated (63), behave 
differently. Our data with LFA-1” T cell clones confirm 
and extend for the greater part those obtained by Haskard
et al. (64) and Schwartz et al. (57), who studied adhesion 
of LFA-1" EBV-transformed B lymphoblastoid cell lines 
to cultured EC. However, in contrast to the finding by 
Schwartz et al. (57) we generally observed that adhesion 
of LFA-1“ T cell clones to unstimulated EC could not be 
inhibited by an antibody to VLA-4a. In our hands unstim­
ulated EC did not express the counterstructure VCAM-1. 
Possibly differences in culture conditions of EC, notably 
the presence of xenogeneic serum and ECGF shortly 
before the adhesion experiment and the presence of 
serum during the experiments described by Schwartz et 
al., may have contributed to slight stimulation of EC. We 
avoided the use of serum during the adhesion test, and 2 
days before the assay the EC were deprived of ECGF and 
heparin. Moreover, we cultured the EC in human serum 
only. However, in one experiment with LAD4 cells (Fig. 
7), in which a particular batch of human serum was 
used, the EC showed morphologically in culture an elon­
gated appearance similar to TNF-a-activated EC, In this 
particular case inhibition by anti-VLA-4 can be observed, 
supporting the notion that particular culture conditions 
may stimulate VCAM-1 expression.
Recently, Kavanaugh et al. (58) also demonstrated that 
LAD T cells bind to endothelium by a VLA-4/VCAM-1 
dependent mechanism (58). In contrast with their find­
ings, we did not observe VLA-4-mediated binding of LAD 
T cells to unstimulated EC, but this may be a result of 
differences in the culture conditions, as discussed above. 
Furthermore, we observed repeatedly that adhesion of 
LFA-1* T cells to EC (except Jurkat, which is discussed 
below) and to TNF-a-stimulated EC could not signifi­
cantly be inhibited by VLA-4 or VCAM-1 antibodies even 
in the presence of anti-LFA-1 or anti-CD 18 antibodies. 
This discrepancy may be a result of differences in the T 
cell clones used or differences in stimulation of EC (4 vs 
24 h). Binding of LFA-1~ T cell clones to stimulated EC is 
dependent on VLA-4 both in our studies and in those of 
Kavanaugh.
A low number of Jurkat T cells, which showed a normal 
expression of LFA-1, adhered to unstimulated EC. In 
contrast to LFA-1* T cell clones, the enhanced adhesion 
of Jurkat T cells to stimulated EC could be inhibited by 
mAb to VLA-4, similar to what we observed with LFA-1- 
deficient T cells. These and earlier observations that 
LFA-1 needs to be activated to enable cell adhesion (65, 
66) indicate that the LFA-1 molecules on Jurkat cells 
might not be activated. Preliminary experiments with 
mAb NKI-L16 directed against the a-chain of LFA-1, 
which is able to activate LFA-1 (67), confirm this obser­
vation (Y. van Kooyk, unpublished observations).
Stimulation of LFA-1* T cells by PMA increased adhe­
sion of these cells to unstimulated EC, and this effect 
was completely LFA-1 dependent. This is in concordance 
with previous observations (66) and those of others (65), 
suggesting that LFA-1-dependent adhesion requires ac­
tivation of LFA-1. In contrast, we repeatedly found that 
PMA was not able to enhance adhesion of LFA-1* T cells 
to TNF-a-stimulated EC despite a much higher ICAM-1 
expression on the EC, Similar results have been obtained 
by Kavanaugh et al. (58) with LFA-1* T cell clones. This 
is in contrast to the data obtained with LFA-1* T lym­
phocytes from peripheral blood, which, upon activation 
with phorbol ester, showed enhanced adhesion to IL-1- 
stimulated EC (14, 53, 54). This enhanced adhesion of 
phorbol ester-activated LFA-1* T lymphocytes to IL-1-
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stimulated EC was, however, inhibited by mAb to LFA-1 
to the level obtained with resting T lymphocytes (14, 53). 
These results suggest that phorbol ester-enhanced adhe­
sion of resting LFA-1* lymphocytes to IL-1-activated EC 
is also LFA-1 dependent. However, our findings suggest 
that compared with resting T lymphocytes from periph­
eral blood, LFA-1* T cell clones use a different pathway 
for adhesion to activated EC.
We cannot completely rule out that the VLA-4/VCAM- 
1 pathway does not play a role in adhesion of the LFA-1* 
T cell clones to EC. The possibility exists that an as yet 
unknown receptor/ligand pair contributes that much to 
adhesion of cloned T cells to EC that VLA-4/VCAM-1 
interaction is obscured. However, other explanations are 
also possible, such as signals generated after the inter­
action of LFA-1 with ICAM-1 and/or ICAM-2, which may 
stimulate other adhesion pathways. A role for CD l ib  
(which Is highly expressed on JS136 cells) in adhesion to 
activated EC can, however, be excluded since mAb to the 
/?2-subunit of the leukocyte integrins did not inhibit the 
adhesion of JS136 or HY827 to TNF-a-stimulated EC. An 
additional possibility to be considered is that the LFA-1/ 
VLA-4-independent component of binding represents 
adhesion to matrix components that have been secreted 
upon activation of the EC rather than to an EC ligand. 
More experiments are necessary to prove this.
In a number of experiments the adhesion of LFA-1* 
and LFA-1" T cells to unstimulated and rTNF-a-stimu- 
lated EC was markedly influenced by mAb to the Hermes- 
1 Ag (CD44), known to induce homotypic aggregation of 
the EBV-transformed B cell line JY within 35 min (36), 
This result may be explained in several ways. Preincu­
bation of T cells with anti-CD44 may have caused T cell 
aggregation, resulting in a higher number of T cells that 
bound to EC because of T cell/T cell interactions. How­
ever, microscopic examination at the end of the test did 
not support this possibility. Alternatively, cross-linking 
by mAb of CD44 molecules on EC and lymphocytes may 
explain enhanced binding. Finally, analogous to the ob­
servations with mAb NKI-L16 to LFA-1 (67), enhanced 
affinity of the CD44 molecule for its ligand hyaluronate 
(68) after binding of the antibody to a particular epitope 
of the CD44 antigen cannot be excluded.
Because adhesion of LFA-1-expressing T cell clones to 
TNF-a-stimulated EC could not be inhibited significantly 
by any of the mAb examined, we speculate that the latter 
adhesion is dependent on a hitherto unknown adhesion 
molecule.
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